179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
17 citations
,
May 2023 in “Pharmaceutics” This review highlights the potential of microneedles for immunotherapy, emphasizing their ability to enhance immune responses and reduce side effects through precise and stimuli-responsive delivery, especially in tumor treatment, while also noting the limitations and areas for improvement in current systems.
13 citations
,
October 2021 in “International Journal of Molecular Sciences” In this study, an immortalized MSC line from human adipose tissue showed potential for applications in regenerative medicine and inflammatory diseases through production of active factors, demonstrated in vitro.
12 citations
,
May 2016 in “British Journal of Dermatology” This report describes a rare case of epidermolysis bullosa acquisita in a child developing during therapy with squaric acid dibutyl ester for alopecia areata, suggesting a possible link between the medication and disease onset.